Targeting Mutant P53 in Cancer: the Latest Insights

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2019 Jul 7

PMID 31277687

Citations 14

Authors

Silvia Di Agostino

Giulia Fontemaggi

Sabrina Strano

Giovanni Blandino

Gabriella DOrazi

Affiliations

Soon will be listed here.

Abstract

This commentary wishes to highlight the latest discoveries in the mutant p53 field that have been discussed in the 8th p53 Mutant Workshop 2019, held in Lyon. TP53 mutant (mutp53) proteins are involved in the pathogenesis of most human cancers. Mutp53 proteins not only lose wild-typ53 function but, in some circumstances, may acquire novel oncogenic functions, namely gain-of-function (GOF), which lead to aberrant cell proliferation, chemoresistance, disruption of tissue architecture, migration, invasion and metastasis. Decoding the TP53 mutational spectrum and mutp53 interaction with additional transcription factors will therefore help to developing and testing novel and hopefully more efficient combinatorial therapeutic approaches.

Citing Articles

TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond.

Wu Q, Nandi D, Sharma D Cancer Metastasis Rev. 2024; 44(1):16.

PMID: 39644332 PMC: 11625080. DOI: 10.1007/s10555-024-10226-2.

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).

Tornesello M Int J Mol Med. 2024; 55(1).

PMID: 39450536 PMC: 11554381. DOI: 10.3892/ijmm.2024.5448.

Bioinformatics analysis of BIRC5 in human cancers.

Ye H, Ma B, Meng G, Tao S, Wang Y, Chen Z Ann Transl Med. 2022; 10(16):888.

PMID: 36111008 PMC: 9469138. DOI: 10.21037/atm-22-3496.

Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.

Li J, Lama R, Galster S, Inigo J, Wu J, Chandra D Mol Cancer Ther. 2022; 21(4):535-545.

PMID: 35131878 PMC: 10258866. DOI: 10.1158/1535-7163.MCT-21-0728.

Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma.

Chang J, Tseng C, Lu P, Wang Y J Pers Med. 2022; 12(1).

PMID: 35055327 PMC: 8780757. DOI: 10.3390/jpm12010012.

References

Lozano G . The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev. 2007; 17(1):66-70. DOI: 10.1016/j.gde.2006.12.003. View

Frixa T, Donzelli S, Blandino G . Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers (Basel). 2015; 7(4):2466-85. PMC: 4695904. DOI: 10.3390/cancers7040904. View

Miranda P, Buckley D, Raghu D, Pang J, Takano E, Vijayakumaran R . MDM4 is a rational target for treating breast cancers with mutant p53. J Pathol. 2017; 241(5):661-670. DOI: 10.1002/path.4877. View

Guha T, Malkin D . Inherited Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med. 2017; 7(4). PMC: 5378014. DOI: 10.1101/cshperspect.a026187. View

Ballinger M, Best A, Mai P, Khincha P, Loud J, Peters J . Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017; 3(12):1634-1639. PMC: 5824277. DOI: 10.1001/jamaoncol.2017.1968. View